Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) will present a late-breaking abstract at the 10th ESWI Influenza Conference in Valencia, Spain, Oct 20-23, 2025.

The presentation, titled "Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study," will be delivered by Voon Ong, Ph.D. in the Late Breakers: Novel and Outstanding Discoveries session on Thursday, October 23, 2025, 2:00-3:30 pm CET.

News Market Reaction – CDTX

+2.07%

8 alerts

+2.07% News Effect

+3.6% Peak in 1 hr

+$62M Valuation Impact

$3.07B Market Cap

0.0x Rel. Volume

On the day this news was published, CDTX gained 2.07%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $62M to the company's valuation, bringing the market cap to $3.07B at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain.

Presentation details are summarized below:

Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study.

Presenter: Voon Ong, Ph.D.

Session: Late Breakers: Novel and Outstanding Discoveries

Session Date and Time: Thursday, October 23, 2025, 2:00-3:30 pm CET

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak^® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com

FAQ

When will Cidara Therapeutics (CDTX) present at the ESWI 10th Influenza Conference?

Cidara will present on Thursday, October 23, 2025, 2:00-3:30 pm CET.

What is the title of Cidara's late-breaking abstract at ESWI 2025?

The title is "Translational efficacy of CD388...application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study."

Who is presenting Cidara's abstract on CD388 at ESWI 2025?

The presenter is Voon Ong, Ph.D..

Which session will Cidara's presentation appear in at the ESWI conference?

It will appear in the Late Breakers: Novel and Outstanding Discoveries session.

What topic does Cidara's ESWI presentation on CD388 cover?

It covers translational efficacy of CD388 in mouse influenza models and application to prevention efficacy from the Ph2b NAVIGATE study.

Where and when is the ESWI 10th Influenza Conference taking place?

The conference runs October 20-23, 2025 in Valencia, Spain.